Nnukwu ịdị ọcha 540737-29-9 Tofacitinib citrate maka JAK Pathway Inhibitor
Ngwaahịaaha | Citrate nke Tofacitinib |
Ụdị okwu | (3R,4R) -1- (Cyanoacetyl) -4-methyl-N-methyl-N-1H-pyrrolo [2,3-d] pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3 - propanetricarboxylate;CP 690500-10;CP 690550-10;(3R,4R) -4-Methyl-3- (methyl-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino) -beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate |
CAS Mba. | 540737-29-9 |
Ọdịdị | Gbanyụọ ọcha na ntụ ntụ ọcha |
Usoro ihe omimi | C16H20N6OC6H8O7 |
Ibu molekụla | 504.50 |
Ngwa | Ọkwa ọgwụ ma ọ bụ ebumnuche nyocha |
Nkwakọ ngwaahịa | Dị ka arịrịọ gị si dị |
Nchekwa | Chekwaa n'ime akpa siri ike, nke na-enweghị ọkụ n'ebe dị mma |
Tofacitinib Citrate (CAS #540737-29-9) | ||
NGWA | Ọkọlọtọ | Nsonaazụ |
Ọdịdị | Gbanyụọ ọcha na ntụ ntụ ọcha | Gbanyụọ ntụ ntụ ọcha |
njirimara | HPLC;IR;HNMR | Na-akwado |
Solubility | Soluble na DMSO na 100mg / ml, soluble nke ukwuu na ethanol, obere soluble na mmiri wdg. | Na-akwado |
Ọnwụ na ihicha | ≤0.5% | 0.12% |
Ihe fọdụrụ na mgbanye | ≤0.1% | 0.05% |
Ọla dị arọ | ≤10ppm | Na-akwado |
Ihe ndị emetụtara | Diasteromer (RS+SR) ≤0.1% Otu adịghị ọcha ≤0.15% Mkpokọta adịghị ọcha ≤1.0% | 0.05% 0.14% 0.18% |
Enantiomorphism Isomers | ≤0.2% | Na-akwado |
Ihe mgbaze fọdụrụnụ | Ethanol ≤5000ppm Methanol ≤3000ppm Toluene ≤890ppm | Na-akwado |
Citrate ọdịnaya | 36.2% ~ 40% | 37.8% |
Ịdị ọcha | ≥99.0% | 99.38% |
Nyocha | 60.68% ~ 63.16% nke Tofacitinib INN 98% ~ 102% nke Tofacitinib Citrate INN | 62.04%
99.12% |
Mmechi: Emebere ya |
Ozi ụlọ ọrụ
√ Ahụmahụ zuru oke nke oyi akwa na ụlọ ọrụ mmepụta ihe na ndị na-eso ụzọ teknụzụ nwere nkà; √ Quality bụ mgbe anyị n'elu echiche, siri ike QC usoro; √ 11 afọ nwere ahụmahụ mbupụ ahịa otu; √ ụlọ nyocha R&D nọọrọ onwe ya; √ Ụlọ ọrụ GMP abụọ bịanyere aka na ogologo oge; √ Akụ bara ụba nke ọtụtụ ụlọ ọrụ na-abaghị uru maka ọrụ ahaziri iche; √ Ndị otu na-arụ ọrụ nke ọma na ụzọ na-agbanwe agbanwe.Dee ozi gị ebe a ziga anyị ya